Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Beuselinck

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
BJU International|July 16, 2016
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinibBenoit Beuselinck, Johnny Jean-Baptiste, Patrick Schöffski, et al.
American Journal of Cancer Research|June 9, 2023
María Santos, Javier Lanillos, Eduardo Caleiras, et al.
Urologic Oncology|May 21, 2020
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitorsLorenz Haaker, Loesia Tryssesoone, Inne Renders, et al.
Oncoimmunology|October 14, 2024
Trial watch: anticancer vaccination with dendritic cellsFrancisca Borges, Raquel S Laureano, Isaure Vanmeerbeek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2025
High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockadeLucia Carril-Ajuria, Ronan Flippot, Marie Naigeon, et al.
Clinical Genitourinary Cancer|January 14, 2020
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell CarcinomaJ Connor Wells, Jeffrey Graham, Benoit Beuselinck, et al.
European Urology|September 20, 2020
Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter CollaborationEduard Roussel, Giovanni Tasso, Riccardo Campi, et al.
Cancer Research Communications|April 20, 2026
Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell CarcinomaLisa Kinget, Edward Scott McTaggart, Octavie Demeulenaere, et al.
Clinical Genitourinary Cancer|December 12, 2018
Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With SunitinibMaxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
BJU International|July 16, 2016
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinibBenoit Beuselinck, Johnny Jean-Baptiste, Patrick Schöffski, et al.
American Journal of Cancer Research|June 9, 2023
María Santos, Javier Lanillos, Eduardo Caleiras, et al.
Urologic Oncology|May 21, 2020
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitorsLorenz Haaker, Loesia Tryssesoone, Inne Renders, et al.
Oncoimmunology|October 14, 2024
Trial watch: anticancer vaccination with dendritic cellsFrancisca Borges, Raquel S Laureano, Isaure Vanmeerbeek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2025
High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockadeLucia Carril-Ajuria, Ronan Flippot, Marie Naigeon, et al.
Clinical Genitourinary Cancer|January 14, 2020
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell CarcinomaJ Connor Wells, Jeffrey Graham, Benoit Beuselinck, et al.
European Urology|September 20, 2020
Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter CollaborationEduard Roussel, Giovanni Tasso, Riccardo Campi, et al.
Cancer Research Communications|April 20, 2026
Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell CarcinomaLisa Kinget, Edward Scott McTaggart, Octavie Demeulenaere, et al.
Clinical Genitourinary Cancer|December 12, 2018
Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With SunitinibMaxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Pageof 12